Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

CLASS ACTION UPDATE for OTLY, AHCO and SPPI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

AHCO, OTLY

NEW YORK, NY / ACCESSWIRE / September 9, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

OTLY Shareholders Click Here: https://www.zlk.com/pslra-1/oatly-group-ab-loss-submission-form?prid=19459&wire=1
AHCO Shareholders Click Here: https://www.zlk.com/pslra-1/adapthealth-corp-f-k-a-dfb-healthcare-acquisitions-corp-loss-submission-form?prid=19459&wire=1
SPPI Shareholders Click Here: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?prid=19459&wire=1

* ADDITIONAL INFORMATION BELOW *

Oatly Group AB (NASDAQ:OTLY)

OTLY Lawsuit on behalf of: investors who purchased May 20, 2021 - July 15, 2021
Lead Plaintiff Deadline : September 24, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/oatly-group-ab-loss-submission-form?prid=19459&wire=1

According to the filed complaint, during the class period, Oatly Group AB made materially false and/or misleading statements and/or failed to disclose that: (a) Oatly overinflated its gross margins, revenue, capital expenditure, and market share financial metrics; (b) the Company overstated its sustainability practices and impact; (c) the Company exaggerated its growth in China; and (c) as a result of the foregoing, Oatly's statements about its operations, business, and prospects were misleading during the Class Period.

AdaptHealth Corp. f/k/a DFB Healthcare Acquisitions Corp. (NASDAQ:AHCO)

AHCO Lawsuit on behalf of: investors who purchased November 11, 2019 - July 16, 2021
Lead Plaintiff Deadline : September 27, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/adapthealth-corp-f-k-a-dfb-healthcare-acquisitions-corp-loss-submission-form?prid=19459&wire=1

According to the filed complaint, during the class period, AdaptHealth Corp. f/k/a DFB Healthcare Acquisitions Corp. made materially false and/or misleading statements and/or failed to disclose that: (i) AdaptHealth had misrepresented its organic growth trajectory by retroactively inflating past organic growth numbers without disclosing the changes, in violation of Securities and Exchange Commission regulations; (ii) accordingly, the Company had materially overstated its financial prospects; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

SPPI Lawsuit on behalf of: investors who purchased December 27, 2018 - August 5, 2021
Lead Plaintiff Deadline : November 1, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?prid=19459&wire=1

According to the filed complaint, during the class period, Spectrum Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/663470/CLASS-ACTION-UPDATE-for-OTLY-AHCO-and-SPPI-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today